drugset / Trial / NCT02489760
Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study
RandomizedCrossoverOpen-labelTreatment
Summary
To determine the safety and efficacy of switch effects to adalimumab in etanercept-treated AS patients.
Timeline
- Start
- 2008-07
- Primary completion
- 2015-12
- Completion
- 2016-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Etanercept | Protein / enzyme biologic | 25 mg | Subcutaneous |
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | Subcutaneous |